The introduction of Cesium-131 represents the culmination of decades of work and millions of dollars of investment. Today medical centers, hospitals and clinics across the United States offer this breakthrough treatment. IsoRay MedicalTM was founded in Richland, Washington in 1998 to develop, manufacture and market isotopes for use in the medical treatment of various malignant diseases. Company founders included recognized experts in the medical isotope field, including Lane A. Bray, chief chemist of IsoRay MedicalTM, who developed the patented process for economically separating and purifying Cesium-131. In March 2003 IsoRay MedicalTM Inc. received clearance to market Cesium-131 from the Food and Drug Administration for the treatment of prostate, breast, liver, brain, head and neck cancers and other malignant disease. In October of 2004, a patient was first treated with Cesium-131 at the University of Washington Medical Center. Beginning more than 40 years ago, Cesium-131 was the first choice over other radioactive medical isotopes, although scientific and economic considerations prevented its development. Once these hurdles were overcome, IsoRay MedicalTM, Inc. was formed to bring the new treatment tool to market. The Cesium-131 Brachytherapy Seeds and our GliaSite balloon catheter offers physicians and their patients another option utilizing a revolutionary new choice in isotope for the treatment of numerous cancers by combining Cs-131's significantly shorter half-life with a high level of energy. While currently treating Brain cancer, Head & Neck cancer, Lung cancer, Colon cancer, Ocular cancer, Gynecologic cancer and Prostate cancer using Cesium-131 is only the first step for IsoRay. The company expects to broaden it's product offering with the development of protocols for the treatment of breast, esophageal, liver, pancreatic and other crippling malignancies.